47 -2 (88) 2026 - Kurbanov Dj.Dj., Navruzova R.S. - DYNAMICS OF ANGIOGENIC AND ANTIANGIOGENIC PROTEINS DURING TREATMENT

DYNAMICS OF ANGIOGENIC AND ANTIANGIOGENIC PROTEINS DURING TREATMENT

Kurbanov Dj.Dj. - Tashkent State Medical University

Navruzova R.S. - Tashkent State Medical University

Khamidova Z.B. - Tashkent State Medical University

Resume

To evaluate the dynamics of angiogenic and antiangiogenic proteins in pregnant women with gestational arterial hypertension (GAH) and moderate or severe preeclampsia (PE). The study revealed that in moderate PE, protein levels are sharply elevated compared to controls and women with GAH, reflecting profound placental hypoxia. In severe PE, disturbances are most pronounced; therefore, the decision to prolong pregnancy must be made cautiously, taking into account the compensatory clinical indicators of both mother and fetus.

Keywords: gestational arterial hypertension, preeclampsia, angiogenic proteins, antiangiogenic proteins, PlGF, sFlt-1, angiopoietin, α1-microglobulin, blood, urine.

First page

231

Last page

236

For citation:Kurbanov Dj.Dj., Navruzova R.S., Khamidova Z.B. - DYNAMICS OF ANGIOGENIC AND ANTIANGIOGENIC PROTEINS DURING TREATMENT//New Day in Medicine 2(88)2026 231-236 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:1:181-192. https://doi.org/10.1016/S0029-7844(03)00475-7
  2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:5:1122-1131. https://doi.org/10.1097/01.aog.0000437382.03963.88
  3. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:5:416-441. https://doi.org/10.1016/S1701-2163(15)30588-0
  4. Jhee JH, Lee S, Park Y, Lee SE, Kim YA, Kang SW, Kwon JY, Park JT. Prediction model development of late-onset preeclampsia using machine learning-based methods. PLoS One. 2019;14:8:e0221202. https://doi.org/10.1371/journal.pone.0221202
  5. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. 2008;78:1:93-100.
  6. Sibai BM. Biomarker for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol. 2007;197:1:1-2. https://doi.org/10.1016/j.ajog.2007.04.021
  7. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol. 2004;103:2:219-224. https://doi.org/10.1097/01.aog.0000107291.46159.00
  8. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:7:672-683. https://doi.org/10.1056/nejmoa031884
  9. Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:2:175.e1-175.e1756. https://doi.org/10.1016/j.ajog.2007.08.052
  10. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:1:66-74. https://doi.org/10.1002/pd.2660

    file

    download